149 related articles for article (PubMed ID: 2117417)
1. WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.
Kaatz GW; Seo SM
Antimicrob Agents Chemother; 1990 Jul; 34(7):1376-80. PubMed ID: 2117417
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.
Jones RN; Barry AL
Antimicrob Agents Chemother; 1990 Feb; 34(2):306-13. PubMed ID: 2327779
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of T-3761, a new fluoroquinolone.
Muratani T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
Smith KR; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
[TBL] [Abstract][Full Text] [Related]
5. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.
Kojima T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1990 Jun; 34(6):1123-7. PubMed ID: 2393270
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.
Eliopoulos GM; Klimm K; Rice LB; Ferraro MJ; Moellering RC
Antimicrob Agents Chemother; 1990 Jun; 34(6):1154-9. PubMed ID: 2393275
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis.
Noskin GA; Mehl P; Warren JR
Antimicrob Agents Chemother; 1993 Nov; 37(11):2470-3. PubMed ID: 8285636
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.
Shonekan D; Mildvan D; Handwerger S
Antimicrob Agents Chemother; 1992 Jul; 36(7):1570-2. PubMed ID: 1324649
[TBL] [Abstract][Full Text] [Related]
11. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
Hoban D; Grabowski M; Koss J; Weselowski V
Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
[TBL] [Abstract][Full Text] [Related]
12. Spontaneously occurring staphylococcal mutants resistant to clinically achievable concentrations of ciprofloxacin and temafloxacin.
Barry AL; Pfaller MA; Fuchs PC
Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):243-6. PubMed ID: 1317799
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the new fluoroquinolone CP-99,219.
Neu HC; Chin NX
Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.
Bremm KD; Petersen U; Metzger KG; Endermann R
Chemotherapy; 1992; 38(6):376-87. PubMed ID: 1288961
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
Sedlock DM; Dobson RA; Deuel DM; Lesher GY; Rake JB
Antimicrob Agents Chemother; 1990 Apr; 34(4):568-75. PubMed ID: 2344163
[TBL] [Abstract][Full Text] [Related]
17. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
[TBL] [Abstract][Full Text] [Related]
18. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
